Research and Markets: Hemorrhagic Fever - Pipeline Review, H1 2013

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7tqlnp/hemorrhagic_fever) has announced the addition of the "Hemorrhagic Fever - Pipeline Review, H1 2013" report to their offering.

'Hemorrhagic Fever - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhagic Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever.

Scope

• A snapshot of the global therapeutic scenario for Hemorrhagic Fever.
• A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Hemorrhagic Fever pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Companies Involved in Hemorrhagic Fever Therapeutics Development

• Sanofi-Aventis
• Pfizer Inc.
• Exelixis, Inc.
• Threshold Pharmaceuticals, Inc.
• Constellation Pharmaceuticals, Inc.
• Axelar AB
• RECEPTA Biopharma S.A.
• Coridon Pty Ltd

Drug Profiles

• cabazitaxel
• BET Inhibitor Program
• P-798
• Epstein Barr Virus Vaccine
• Andrographolide
• Mer Receptor Tyrosine Kinase Inhibitors
• Mer Antibody
• RebmAb-500

For more information visit http://www.researchandmarkets.com/research/7tqlnp/hemorrhagic_fever